Quantum-Si

Quantum-Si, Inc. develops a protein sequencing platform of proteomics. It offers single molecule analysis, and democratizing its use by providing researchers and clinicians access to the proteome. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Guilford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quantum-Si reports mixed Q4 results, eyes growth with Carbon launch

Quantum-Si's Q4 2022 earnings call showcased a mix of financial challenges and operational successes. The company's focus on innovation, product development, and commercialization efforts positions it well for future growth and impact in the healthcare industry.

Quantum-Si reports Q1 revenue growth, plans marketing expansion

Quantum-Si's Q1 2023 performance showed promising revenue and customer orders, but challenges persist with high operating expenses leading to an EBITDA loss. The company's focus on innovation and market expansion presents growth opportunities in the coming quarters.

Quantum-Si faces revenue hurdles in Q2 2023 earnings call

Quantum-Si's Q2 2023 performance showed revenue and gross profit figures, but challenges in meeting expectations led to significant losses. The company's strengths lie in the commercial team's positive feedback and strategic hires, while opportunities exist in realignment and disciplined growth strategies. Addressing revenue challenges, R&D alignment, and customer feedback are key priorities for Quantum-Si.

Quantum-Si (QSI) reports Q3 revenue growth and eyes global expansion

Quantum-Si (QSI) shows promising progress in revenue growth, product innovation, and market interest, despite facing challenges in expenses and profitability.
The company's strategic focus on commercializing key products and expanding internationally presents significant growth opportunities in the coming quarters.
Overall, QSI's financial performance, product roadmap, and market strategies position it for future success, pending effective execution and cost management.

Quantum-Si reports Q4 loss, eyes growth with innovative sequencing

Quantum-Si's Q4 2023 performance reflects a focus on innovation and market expansion despite a net loss, with strong revenue guidance for 2024.
The company's strategic strengths lie in its disruptive technology, product development initiatives, and market positioning in key regions.
Challenges in managing expenses and achieving profitability underscore the need for operational efficiency and competitive differentiation.
Amidst challenges, Quantum-Si has opportunities to drive growth through new product launches, market expansion, and meeting increasing market demand.

Quantum-Si reports revenue growth and strategic priorities for 2024

Quantum-Si's Q2 2024 performance showed revenue growth and improved net loss.
The company's strengths lie in financial reserves, guidance, and strategic priorities.
Challenges include managing expenses and balancing financial strength with innovation.
Opportunities arise from new board additions, technology potential, and market focus.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum-Si, Inc. engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing, the ability to sequence proteins in a massively parallel fashion. It can be used for the study of nucleic acids. Its platform includes Carbon automated sample preparation instrument, Platinum NGPS instrument, Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Quantum-Si to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Third Quarter 2021 Financial Results on November 11, 2021

Quantum-Si to Report Third Quarter 2021 Financial Results on November 11, 2021

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life science tools company commercializing a unique protein sequencing platform, announced today that they have expanded their Platinum early access program to ten sites, with participation from leading academic centers and key industry partners. The early access program introduces the Platinum single molecule sequencing system to key opinion leaders across the globe, for both expan

Quantum-Si Announces Expansion of Early Access Program for the Platinum™ Single Molecule Protein Sequencing Platform

Butterfly Network

GUILFORD, Conn.--(BUSINESS WIRE)-- #Covid19--Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM). The $8.1 million contract will facilitate the development and scale up manufacturing of Detect's PCR-quality rapid at-home Covid-19 test to meet national testing demand. The Detect Covid-19 Test, curre

Detect™ Selected by NIH to Scale Manufacturing of PCR-Quality Rapid At-Home Covid-19 Test

Novel semiconductor-based next generation protein sequencing platform targeting $64B+ proteomics market in 2024 (15% CAGR). Founded by Dr. Jonathan Rothberg, Professor of Genetics at Yale University (who sequenced the first human genome and is known for inventing high-speed, next-generation DNA sequencing).

Quantum-Si: Semiconductor-Based Next Generation Protein Sequencing Platform

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si” or the “Company”), a company pioneering next-generation semiconductor chip-based proteomics, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30, 2021. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, September 29, at 1:20 – 1:50

Quantum-Si Incorporated to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Dynamics Special Purpose Corp

Fate Therapeutics

Khosla Ventures Acquisition Co II

908 Devices

Soaring Eagle Acquisition Corp - Unit

Vuzix

Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.

Cathie Wood Makes Adjustments to Portfolio in August

ARK Fintech Innovation ETF

ARK Innovation ETF

ARK Web x.0 ETF

Invitae

Palantir Technologies

StoneCo

Zillow

Cathie Wood continues to pick up stocks through her ARK Invest ETFs and we're taking a look at some of their top investments for Tuesday. The post Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?

Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?

Quantum-Si incorporated's (QSI) CEO John Stark on Q2 2021 Results - Earnings Call Transcript

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Second Quarter 2021 Financial Results

Quantum-Si Reports Second Quarter 2021 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Second Quarter 2021 Financial Results on August 16, 2021

Quantum-Si to Report Second Quarter 2021 Financial Results on August 16, 2021

Proteomics is a rising star in the multi-omics space. Semiconductor chips specifically designed to identify biology brings the advantages of scalability and Moore's law.

Quantum-Si: Merging Semiconductors With Biology Will Scale Things Fast

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Second Quarter 2021 Financial Results on August 12, 2021

Quantum-Si to Report Second Quarter 2021 Financial Results on August 12, 2021

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Thursday.

Cathie Wood's ARK Invest Buys Over 800,000 Shares of Quantum-Si

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Tuesday.

Cathie Wood's ARK Invest Buys Over 280,000 Shares of Quantum-Si

Proteomics has the potential to revolutionize medicine in potentially the same way that genomics has. The traditional field looks primed for disruption and that effort could hit critical mass soon. Quantum-Si has set forth a business plan to utilize consumables as the primary driver of revenues and achieve a long-term goal of 70% margins.

Proteomics May Be The Future Of Biotech, Quantum-Si Is A Potential Leader

UiPath

Investors looking for strong growth companies should add these two to their watch list.

Cathie Wood Is Investing in These 2 Innovative Stocks

Cathie Wood's ARK Invest Buys Over 350,000 Shares of Quantum-Si

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Monday.

Cathie Wood's ARK Invest Buys Over 460,000 Shares of Quantum-Si

Cathie Wood-led Ark Investment Management has quickly piled up over one million shares in the semiconductor company Quantum-Si Inc (NASDAQ:QSI) since it began trading earlier this month. The popular investment firm on Thursday snapped another 95,199 shares, estimated to be worth about $1 million, in Quantum-Si Inc (NASDAQ:QSI), its sixth straight buy in the stock since June 11, the day it began trading on the Nasdaq.

Cathie Wood Loads Up On Quantum-Si For 6th Straight Session: What You Should Know About This Chip Stock

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today that it has entered into a lease agreement with Phase 3 Real Estate Partners, Inc. to develop a 25,586-square-foot product development and operations facility in San Diego, CA. The new facility, located in Sorrento Mesa, is being designed to scale production and expand research and development efforts. We expect this site will play a vital role in

Quantum-Si Signs Lease for Product Development and Operations Facility in San Diego Biotechnology Hub

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday.

Cathie Wood's ARK Invest Buys Over 270,000 Shares of Quantum-Si

Cathie Wood's ARK Invest Buys Nearly 700,000 Shares of Quantum-Si

HighCape Capital Acquisition Corp.

GUILFORD, Conn. & NEW YORK--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSi” or “the Company”), a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a special purpose acquisition company sponsored by leading healthcare growth equity manager HighCape Capital LP. The business combination and concurrent private placement

News for Quantum-Si Stock (QSI)